Bradda Head Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Today is World Cancer Day. Imagine the contribution that AVO would have been providiing to saving lives, if only the.....
I had two friends who have died of 'inoperable' brain cancers. One of them died last month, the other two years ago. I believe that LIGHT might have saved at least one of them, if AVO had been in the hands of a more capable BoD.
It doesn't make any difference now but the BoD have been shafted by AIM like the rest of us. Don't think 1.9p sp after 230MeV was anticipated making raising funds almost impossible unless this potential investor has a philanthropic nature.
It’s not AIM that’s shafted us, Vanilla, it’s the incompetent BoD. When the 230MeV milestone was met the share price was 24p and things looked great. Odey invested another £6m. Six months later the SP had steadily declined to 2.5p and a strategic review was underway. A major reason for this, imo, was the company blurting out some time after 240MeV that it needed another £70m or so over the next two years with no apparent plan of how to raise this amount. The BoD were asleep at the wheel and complacent.
You are right, where did the huge funding need arise from all of a sudden. It looks like the BOD was already aware of not being going concern well into the end of 2022 and couldn’t get the audit signed and release the annual report . This is only explained by an attempt to somehow announce the debt load and not being going in disgustingly disguised manner, that it’s in the public domain, as they repeatedly tell. This is worthy of investigative reporting, don’t understand why it hasn’t been done yet.
The frustrating thing is that the funding requirement didn’t pop out of nowhere, it would have been pretty well understood well before reaching 230MeV. Running costs were c£20m pa - so that’s £40m over two years - plus the cost of the building for first treatment, plus some manufacturing costs probably. I think they were just very slow at trying to raise the cash.
A typical mistake is to underestimate the time needed for development and the certifications required in medical technology. The 230 MeV was an important milestone, the proof that the engine works. But before the "aircraft can fly safely", everything else has to be right. These are no longer unsolvable problems, that's sure, but it is a lot of work. And it was precisely for these tasks that time and therefore money ran out. On the other hand, you often can't tell investors the real development times because they don't have the patience to wait due to today's expectations that everything has to make a lot of profit very quickly.
A proton therapy system is the largest and most complex medical device in the world. The market for such systems is immense and so are the profits after market launch. But this requires investors who understand this and have the patience. And I think that's what the BoD is not ideal for to find them.
Michael Sinclair, former CEO, once said that he would never have agreed to lead this project if CERN had told him how big it would really be. But then, as it progressed and he realised it, he understood also the potential behind it. There are people I trust to convince investors for such large-scale projects. Michael Sinclair certainly has a good charisma for it and I hope he's still in an active role. Another person, not at AVO, but involved in high tech complex projects is Bertrand Picard, who I would have tried to get into the BoD. He is even not fare from CERN. I had the opportunity to meet him in person in Payern. He has the necessary charisma and vision plus the technology interest for such large-scale projects, which ultimately benefit the general public.
I Want, I think you have a very valid point and I wish I read this advice many years ago when I invested considerably. Are you invested?
@PM44
Yes, I have invested and not a little. Because I know the technology and know that the system can work very well. There are no more technical showstoppers. The system is doomed to be a success once the prototype in Daresbury has been completed and a tumour or water phantom can be irradiated with it. The final financial investment is missing and that is solely the fault of the BoD and there the CEO as he is responsible for this task.
I fear unfortunately, that in this situation, it will hand up in the hands of America or China and make them handsome profits.
The China issue may be more realistic than is currently believed.
A major investor comes from China (a pharmaceutical company, which has secured the distribution rights in China) and P-Cure, the previous supplier of the patient positioning system inclusive Philips CT, is financially linked to China, with a company that is already active in this field. P-Cure had massive financial problems and got involved with this Chinese company. Perhaps someone else here can explain more details.
In any case, P-Cure was financially reorganised but at the same time became a competitor.
The LINAC accelerator technology, which is much cheaper and better at the same time, is still missing.
The BoD also has more than just share packages, which may mean that other priorities play a role. Odey started a sold out of their shares (everyone knows why), which caused the last drop-down of the SP. No-one knows what's happening actually.
As the BoD does everything behind closed doors, there is plenty of room for speculation.
I think it's time that Nicolas Serandour lifts now the secrets that everyone knows where we are.